Genaissance Sees New Life For Vilazodone With Pharmacogenomics
This article was originally published in Pharmaceutical Approvals Monthly
Genaissance will use pharmacogenomics to revive development of the antidepressant vilazodone.
You may also be interested in...
Gene Logic to revive Pfizer drug candidates: Several Pfizer drug candidates not currently in active development could be revived through a partnership with Gene Logic, announced Sept. 27. Gene Logic's Drug Repositioning and Selection Program uses a range of technologies to evaluate a drug's potential utility, and could "restore stalled drug candidates back into [Pfizer's] clinical development pipeline," Gene Logic says. In addition to the "significant number" of candidates from Pfizer, Gene Logic currently is reviewing one stalled Phase II candidate from Millennium and 16 Phase II and III candidates from an undisclosed company. Another firm with plans to develop a pipeline based on in-licensing stalled drug candidates is Genaissance; the firm licensed the antidepressant vilazodone from Merck KgaA in September 2004 (1Pharmaceutical Approvals Monthly October 2004, p. 27)...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011